2Q PREVIEW: Gilead's HIV therapies still carry the day
This article was originally published in Scrip
Executive Summary
While Gilead Sciences’ stock trades on hope for its hepatitis C drug program, the company’s earnings are still dependent on a dominant hold on the HIV therapy market.